Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Rigel Pharmaceuticals Inc is a biotechnology business based in the US. Rigel Pharmaceuticals shares (RIGL) are listed on the NASDAQ and all prices are listed in US Dollars. Rigel Pharmaceuticals employs 169 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $2.42 |
|---|---|
| 52-week range | $2.22 - $5.50 |
| 50-day moving average | $2.65 |
| 200-day moving average | $3.50 |
| Wall St. target price | $7.83 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.09 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.42 from 2022-01-24
| 1 week (2022-01-14) | N/A |
|---|---|
| 1 month (2021-12-23) | -14.79% |
| 3 months (2021-10-25) | -24.61% |
| 6 months (2021-07-23) | -41.26% |
| 1 year (2021-01-25) | -34.24% |
|---|---|
| 2 years (2020-01-24) | -3.97% |
| 3 years (2019-01-25) | 13.62% |
| 5 years (2017-01-25) | 19.21% |
| Revenue TTM | $147.3 million |
|---|---|
| Gross profit TTM | $47.6 million |
| Return on assets TTM | -4% |
| Return on equity TTM | -28.84% |
| Profit margin | -9.85% |
| Book value | $0.29 |
| Market capitalisation | $415.5 million |
TTM: trailing 12 months
We're not expecting Rigel Pharmaceuticals to pay a dividend over the next 12 months.
Rigel Pharmaceuticals's shares were split on a 1:9 basis on 24 June 2003. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rigel Pharmaceuticals shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Rigel Pharmaceuticals shares which in turn could have impacted Rigel Pharmaceuticals's share price.
Over the last 12 months, Rigel Pharmaceuticals's shares have ranged in value from as little as $2.22 up to $5.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rigel Pharmaceuticals's is 1.4227. This would suggest that Rigel Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Rigel Pharmaceuticals, Inc. , a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co. , Ltd.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.